Comparison of the Efficacy of Paclitaxel, Paclitaxel Liposome and Albumin Bound Paclitaxel in Head and Neck Tumors

OBJECTIVE To investigate the efficacy of paclitaxel(PTX), PTX liposome(L-PTX) and albumin bound paclitaxel(nab-PTX) in head and neck tumors. METHODS A total of 69 patients with head and neck cancer who were admitted to our hospital from January 2017 to June 2018 were enrolled. Among them, 31 patients received PTX plus carboplatin as PTX group, 26 patients received L-PTX plus carboplatin as L-PTX group, 12 patients received nab-PTX combined with carboplatin as nab-PTX group. The short-term clinical efficacy and adverse reactions of the 3 groups were compared. RESULTS The response rate of the nab-PTX group was higher than that of the PTX group(66.67% vs 32.26%, χ²=4.209, P=0.040); the incidence of neutropenia in the L-PTX group was higher than in the PTX group(χ²=4.079, P=0.043), and the incidence of leukopenia was higher than in the PTX group(χ²=4.422, P=0.035) and the nab-PTX group(χ²=5.640, P=0.018); the incidence of adverse reactions such as alopecia, nausea and vomiting, diarrhea in the nab-PTX group was lower than that in the PTX group(χ²=5.530, P=0.019; χ²=6.423, P=0.011; χ²=4.438, P=0.035) and L-PTX group(χ²=5.025, P=0.025; χ²=5.025, P=0.025; χ²=5.088, P=0.024), the incidence of peripheral neuritis was lower than that of PTX group(χ²=4.711, P=0.030). CONCLUSION Nab-PTX combined with carboplatin is effective in the treatment of head and neck tumors, and the adverse reactions are milder.